Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice

International Journal of Urology

Volumn 5, Issue 4, 1998, Pages 370-373

  Miki, Tsuneharu ^a,b   Nonomura, Norio ^a   Takaha, Natsuki ^a   Nishimura, Kazuo ^a   Kojima, Yasuyuki ^a   Sawada, Masumi ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; CPT 11; Nude mouse; Renal tumor; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT;

EID: 0031683968     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00369.x     Document Type: Article

References (18)

1. Maldazys J, deKernion J. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-379.
2. deKernion JB. Treatment of advanced renal cell carcinoma: traditional methods and innovative approaches. J Urol 1983;130:2-7.
3. Murphy BR, Rynard SM, Einhorn LH, Loehrer PJ. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. Invest New Drugs 1992; 10:225-230.
4. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for renal cell carcinoma. Urol Clin N Am 1993;20: 303-321.
5. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5947.
6. Furuta T, Yokokura T, Mutai M. Antitumor activity of CPT-11 against rat Walker 256 carcinoma. Jpn J Cancer Chemother 1988;15:2757-2760.
7. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988;21:71-74.
8. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, Hattori T. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990;17:115-120.
9. Miki T, Saiki S, Kinouchi T, Kuroda M, Kiyohara H, Usami M, Sawada M, Kotake T. Human germinal testicular tumors heterotransplanted into nude mice. Jpn J Urol 1988;79:265-273.
10. Miki T, Ishiguro S, Sawada M, Kotake T. Antitumor effect of recombinant human tumor necrosis factor on human testicular tumors heterotransplanted in nude mice. Eur Urol 1994;25:242-247.
11. Miki T, Sawada M, Nonomura N, Kojima Y, Okuyama A, Maeda O, Saiki S, Kotake T. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol 1997;31:92-96.
12. Matsuda M, Osahune M, Nakano E, Kotake T, Sonoda T, Watanabe S, Hada T, Okochi T, Higashino K, Yamamura Y, Abe T. Characterization of an established cell line from human renal carcinoma. Cancer Res 1979;39: 4694-4699.
13. Sugao H, Seguchi T, Nakano E, Sonoda T, Matsuda T, Goto T, Onishi S, Kawaguchi N. Establishment and characterization of new cell lines from human renal cell carcinoma, and the sensitivity to interferon. Human Cell 1991;4: 167-144.
14. Houchens DP, Ovejera AA, Barker AD. The therapy of human tumors in athymic (nude) mice. In: Houchens DP, Ovejera AA (eds) Proceedings of the symposium on the use of athymic (NUDE) mice in cancer research. New York: Fischer, 1978:267-280.
15. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987;84:5565-5569.
16. Cockburn AG, White R, deVera P. Chemotherapy of advanced renal adenocarcinoma. World J Urol 1984;2:136-141.
17. Torti FM.Treatment of metastatic renal cell carcinoma. In:Torti FM (ed) Urologic cancer: chemotherapeutic principles and management. Berlin: Springer-Verlag, 1983: 123-142.
18. Kish JA, Wolf M, Crawford ED, Keimen JT, Bueschen A, Neefe JR, Flanigan RC. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. Cancer 1994;74:916-919.